Market Trends of Unresectable Hepatocellular Carcinoma Industry
This section covers the major market trends shaping the Unresectable Hepatocellular Carcinoma Market according to our research experts:
Chemotherapy Holds Significant Share in the Unresectable Hepatocellular Carcinoma Market
By treatment, the chemotherapy segment is expected to witness significant growth. The major factors fueling the segment's growth are the increasing prevalence of hepatocellular carcinoma, the growing number of drug approvals, and advancements in new treatment options.
For instance, as per a 2021 update by the American Society of Clinical Oncology (ASCO), chemoembolization is a type of chemotherapy treatment similar to hepatic arterial infusion. The same source also reported that drugs are injected into the hepatic artery during this procedure, and the flow of blood through the artery is blocked for a short time. Thus, the chemotherapy stays in the tumor for a longer period, making chemotherapy treatment more effective. Therefore, such factors are boosting the adoption of chemotherapy as a better treatment option for patients suffering from HCC, thereby contributing to the segment's growth.
Furthermore, a news article published in February 2022 detailed a study conducted at Tianjin Cancer Hospital in China. The researchers examined 35 patients with intermediate/advanced HCC at Tianjin Cancer Hospital. The study concluded that in patients with unresectable hepatocellular carcinoma (HCC), the most frequent kind of primary liver cancer, combining PD-1 immune checkpoint suppression with transarterial chemotherapy and Lenvima (lenvatinib) improved prognosis. Such factors increase the adoption of chemotherapy among the patient population, thus driving the segment's growth.
Thus, the factors mentioned above are anticipated to boost the segment's growth over the forecast period.
North America Dominates the Unresectable Hepatocellular Carcinoma Market
Within North America, the United States holds the major share of the market. Factors such as the increasing prevalence of liver cancer in the country, technological advancements in drug development, increasing R&D investments, and the growing geriatric population are expected to drive the US unresectable hepatocellular carcinoma market during the forecast period. According to data by GLOBOCAN 2020, the estimated number of liver and intrahepatic bile duct cancer cases in the country was 42,284 in 2020. The number is expected to reach 52,703 by 2040. Unresectable hepatocellular carcinoma is the most common type of liver cancer. The expected increase in cancer cases in the country may drive the market's growth.
Several market players are engaged in implementing strategic initiatives, thereby contributing to the market's growth. For instance, in February 2022, Eureka Therapeutics Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, reported that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to ET140203 and ECT204 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. In January 2020, AstraZeneca's durvalumab (Imfinzi) and tremelimumab were granted the US FDA Orphan Drug Designation to treat hepatocellular carcinoma (HCC).
Thus, due to the above-mentioned factors, the market is expected to grow significantly in the region over the forecast period.
